The situation
Antibodies directed against tumour-associated antigens have been shown to localise specifically in tumours in animal models and in patients with a variety of malignancies including the common epithelial cancers. They have theoretical potential in the therapy of cancer when given alone or when conjugated to an anti-cancer drug. Anti-tumour activity has been shown in several animal tumour models and in a few small clinical investigations. It is important to investigate the efficacy, safety and quality of this new type of treatment so that any advantages may be offered to patients with cancer without undue delay.
The problem
There is inadequate information on the toxicity to be expected from administration of antibodies and drug-antibody conjugates. It is predictable that existing procedures for phase I and II trials will cover some of the problems but that new procedures need to be defined for others. These include procedures to exclude viruses and polynucleotides from preparations and means of avoiding tissue damage caused by the localisation of antibodies in normal tissues. Guidelines for phase I and II clinical trials of cytotoxic drugs in the treatment of cancer have been agreed by the Cancer Research Campaign Clinical Trials Committee. These have been used as a basis for the proposed procedures for clinical trials with antibodies and drug antibody conjugates with modifications and additions as considered appropriate.
It is recognised that the requirements of the licensing authority in regard to physicians undertaking a limited trial of a drug in their own patients are less demanding than those required of a drug company seeking a clinical trial certificate. The cost of toxicology, which must be borne by grants from government or charitable sources, would be prohibitive and destructive to the venture if the safety requirements of the licensing authority were set too high.
The aim of this document is to establish guidelines for the quality and safety of antibodies and drug antibody conjugates produced in hospitals and university departments and to establish principles on which phase I trials of these agents will be conducted. 1.3 The special position of antitumour drugs It has become evident that human cancer is, from the point of view of systemic therapy, a uniquely human disease. Although similar cancers can be induced and studied in many animal species, only generalisations about the disease and its course are obtained. To acquire more effective antitumour drugs in humans it has become necessary to exploit the close interplay of the human response to a foreign chemical and the vulnerability of the human tumour.
The inadequacy of animal models
The lack of reliably predictive animal models of human cancer implies that a drug's therapeutic potential can only be assessed following careful studies in man. Accordingly there is a strong argument, in the case of potential anticancer drugs, to adopt the minimum animal toxicology requirements which are consistent with safety, so that promising candidates may proceed rapidly to the clinic. The only valid information obtainable from animals is an indication of anti-tumour activity, an indication of antibody localisation in xenografts of human tumours and an indication of maximum drug levels with which to commence human toxicity and anti-tumour trials.
1.5 The aim of the minimum toxicological requirement The present document summarises recommendations on the minimum data necessary to satisfy and to assist the clinician contemplating phase I testing with all the information he needs whilst at the same time recognising the cost andfeasibility of obtaining this information in the laboratory. In addition, the recommended procedure for the conduct of the phase I trial itself is presented. 
Stability
Data concerning the binding activity of the antibody and storage conditions (temperature, duration, proteolytic enzyme inhibitors added) should be documented.
2.5 The final product 2.5.1 The appearance, colour, form in which presented should be given.
2.5.2 Precise criteria for the purity of the immunoglobulin product should be established. These should include tests with limits for homogeneity (e.g., by a variety of electrophoretic procedures); specification with limits, for specific activity (antibody activity per unit weight protein) and the presence of aggregates.
2.5.3
The final product should be pyrogen-free.
2.5.4
The final product should be negative on culture for bacteria and mycoplasma and should be filtered before administration.
2.5.5 The antibody should be treated to inactivate viruses either in the final product form or at an earlier stage; the method used should be specified and shown to be efficacious and innocuous (e.g., gamma irradiation or heat treatment). envisaged that studies will be conducted in animals of one sex, usually male.
Unconjugated antibody
If the purity and specificity (with particular reference to 3.1. lb and c) have been shown to be satisfactory it is expected that the results of single dose toxicity studies should be available. These studies will normally be conducted in mouse (i.e. the species frequently used in antibody production) and one other species, e.g. guinea pig or rabbit. The number of animals required is in the order of 6-10 per dose. The dose given should be 10 times that proposed in man on a pro rata basis (e.g. mg kg-1).
In certain circumstances a second dose may be advisable, for example in order to cover the possible need for dose escalation in man. The aim of the study is to identify any untoward or unexpected effect of the antibody. All animals should be sacrificed 14 days after dosing and subjected to gross pathological examination. Histopathology should be carried out on any tissues which are macroscopically abnormal. Haematology will also usually be performed (see Sections 3.2.4 and 3.2.5).
Conjugated antibody (a)
Single dose studies (usually in male animals) i. Antibody linked to a known cytotoxic agent An estimate of the LDIO of the conjugate should be obtained in mice and another species, e.g. guineapig or rabbit using 6-10 animals/dose. It is anticipated that the approximate lethality of the cytotoxic agent alone and the antibody alone will be available.
Animals from these studies treated with the LDIO should be observed and weighed for 14 days and then subjected to full histopathological and haematological investigation (see Sections 3.2.4 and 3.2.5).
(a) ii. Antibody linked to an unknown cytotoxic agent An estimate of lethality (e.g. LD1O) of the cytotoxic agent alone and of the conjugate should be obtained in mice and another species (e.g. rabbit or guinea-pig) using 6-10 animals/dose. Those animals which were treated with the LDIO of the conjugate should be observed and weighed for 14 days and then be subjected to full histopathological and haematological examination (see Sections times the proposed patient dose should be used, for example, in a course, of 5 successive daily treatments in mice and one other species (e.g. rabbit or guinea-pig). Sufficient animals should be used to enable some to be sacrificed at the end of the dosing period and some to be observed and weighed for a subsequent 28 days prior to sacrifice. All animals should be subjected to full histopathological and haematological examination (Sections 3.2.4 and 3.2.5). Should toxicity be evident at this dosage it will be necessary to repeat the experiment using a lower dose in order to ascertain a no or minimal effect level.
Radiolabelled antibody for diagnostic use
If the purity and specificity of the antibody have been shown to be satisfactory it is expected that very limited toxicity testing would be conducted. It is suggested that if the radiolabel is replacing a normal atom or molecule, for example tritium replacing hydrogen, then there is no need for studies other than those outlined for the uncojugated antibody (see Section 3.2.1). Where the radiolabel forms an addition product with the antibody it may be advisable to carry out the studies using a cold product prepared in the same way as the radiolabelled product but for example substituting iodine 127 instead of 131. If this is not possible then toxicity studies should be done using the unconjugated antibody only.
Haematology
For toxicity studies, a total red cell, white cell and platelet count together with differential assessment of white cell components are to be obtained together with a bone marrow smear.
Histology
The following tissues will be examined -bone marrow (squash preparation), kidney, liver, spleen, heart, lung, gut, brain and testis. Any perturbation from normally will be described in detail. Histology of all intercurrent deaths is required.
Clinical eligibility of patients
In addition to the information outlined below, the following publication is recommended for more 
Treatment status (for therapeutic studies)
At least a three week interval since the last dose of other potentially myelosuppresive therapy and recovery from reversible toxicity.
Haematological requirements
Minimal haematological requirements: WBC > 3,000mm 3; platelets > 100,000 mm 3 (excluding patients with acute leukaemia).
Biochemical status
Minimal biochemical parameters: normal values for organs related to drug metabolism and excretion or related to major toxic manifestations. Deviations up to 25% above the upper limit of normal liver function will be acceptable however.
Consent
No patient will be entered into the study without his or her consent or that of a parent or guardian for those under 16 years, following a full explanation of the purpose and limited expectations of the study. the following Usually two patients per nontoxic dose level but at least three patients at levels producing limiting toxicity. Seven to ten patients at drug levels with acceptable, reversible toxicity.
Serial observations
Appendices 3, 4, 6 and 7 summarise minimum requirements. Additional parameters and/or increased frequency of determinations might be required, depending on animal toxicology and on the needs for the best clinical management of the patient.
7. Drug administration 7.1 Formulation See 2.3-2.5.
Drug administration
Means to treat anaphylaxis should be available. Route to be stated, e.g. i.v. bolus or infusion over a defined time period.
Initial dose schedule
The maximum starting dose will be based on 1/10th of the LDIO in mouse given i.v. An arbitrary dose will be needed if the LD1O cannot be attained but 10 times this dose must have been shown to be at or below the LD10 in mice and in a species other than that from which the antibody originates if the antibody is of mouse or rat origin.
7.4 Initial drug dose Drug doses are given in mgm-2 body surface area. Two patients will be entered at the starting dose level (see Appendix 2).
7.5 Escalation protocol in subsequent patients Subsequent patients will be entered at higher dose levels, if no dose-limiting toxicity occurs at the preceding dose level. Normally 3 patients should be entered at each dose level. Consideration may be given to escalating the dose in the same patient or in different patients although these are likely to give different results if patients become immunised to antibody after 1 or more doses.
The dose increments will diminish as the level of expected toxicity is reached and a commonly used escalation protocol is outlined in Appendix 5.
Timing of admission of subsequent different patients to treatment
A time interval of at least 10 days should pass between administration of a drug to one patient and the admission of the next patient at the same dose level. At least three weeks should pass before entry of further patients into the next higher dose level, in order to take advantage of the experience gained at lower dose levels. The time intervals may be increased as levels of expected drug toxicity are reached.
7.7 Dose modification Consideration should be given to interrupting medication when there is evidence of hypersensitivity, a major adverse effect of bone marrow except in patients with acute leukaemia or whenever other complications occur.
Medication should also be interrupted or discontinued whenever this is regarded to be in the best interests of the patient, irrespective of toxicity.
Duration of drug administration
This will have to be established as experience is gained.
7.9 Duration of study The patients are followed for at least 3 weeks after the last drug dose; longer if there is toxicity.
7.10 Additional dose schedules It may be desirable to explore more than one dose schedule of drug administration (e.g. continuous i.v. infusion or daily 5 day doses).
The starting level for drug dose is 1-2 dose steps below the level of expected toxicity and depends on the experience gained with the initial dose schedule (type of toxicity, reversibility of toxicity, variability of individual tolerance).
7.11 Recording of toxicity and response Appendices 3 and 4 give guidelines to be used in addition to history, examination and any other relevant investigation.
Supportive therapy
Full supportive care and treatment will be given to each patient (antibiotics, transfusions, diet, etc.). Hospitalisation should be recommended for agents with unpredictable toxicity.
Radiotherapy
May be given as a palliative measure. If major areas of haematopoietic tissue need to be irradiated, the patient will be excluded from further study.
Additional chemotherapy
Administration of other antineoplastic agents during the study period disqualifies the patient from the study.
Antidotes
A record of all concurrent non-antitumour drugs used should be provided at the end of the study.
9. Flow of information and records 9.1 Study co-ordinator A co-ordinator will be appointed to collate all studies on a single drug within a group.
Registration
Qualifying patients are registered with the study coordinator for assignment of drug dose and starting date. 9.5 Flow sheets Flow sheets including tumour measurements will be used to record day to day observations on symptoms, signs and laboratory data.
Summary sheet See Appendix 8.
A summary sheet will be prepared by the study co-ordinator.
9.7 Sudden toxicity procedure The study co-ordinator is called at once in case of pronounced toxicity; he/she will inform the investigators in charge of other patients in the study.
Data availability
The summary form and flow sheets to be made available to the Phase I Clinical Trials Committee at the completion of the study, or at any other time suggested by the Phase I Clinical Trials Committee.
Regulatory requirements
A form for doctors and dentists exemption certificates must be submitted to the DHSS (form MLA 162). Bone marrow where indicated
The determination of obligatory and non-obligatory parameters will be made for each agent during the production of each individual protocol.
Translation of MTD in mice to Phase I starting dose in humans It was concluded by Freireich et al. (1) and Owens (2) that on a mgm-2, the MTD was, on average, similar in each animal species. It was concluded that: 1/6 LDIO in mouse could be used provided this amount is not life threatening or lethal in the dog.
An alternative in the absence of dog toxicity data is to use 1/10th LD10 (mouse) that would probably always be tolerated in the dog. The latter is the recommended procedure. 
